- Home
- WLAC vs NBTX Comparison
WLAC vs NBTX Comparison
Compare WLAC & NBTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WLAC
- NBTX
- Stock Information
- Founded
- WLAC 2024
- NBTX 2003
- Country
- WLAC United States
- NBTX France
- Employees
- WLAC N/A
- NBTX N/A
- Industry
- WLAC
- NBTX Biotechnology: Pharmaceutical Preparations
- Sector
- WLAC
- NBTX Health Care
- Exchange
- WLAC Nasdaq
- NBTX Nasdaq
- Market Cap
- WLAC 171.5M
- NBTX 201.9M
- IPO Year
- WLAC 2024
- NBTX 2020
- Fundamental
- Price
- WLAC $9.96
- NBTX $3.75
- Analyst Decision
- WLAC
- NBTX Strong Buy
- Analyst Count
- WLAC 0
- NBTX 1
- Target Price
- WLAC N/A
- NBTX $12.00
- AVG Volume (30 Days)
- WLAC 9.5K
- NBTX 8.9K
- Earning Date
- WLAC 01-01-0001
- NBTX 09-18-2024
- Dividend Yield
- WLAC N/A
- NBTX N/A
- EPS Growth
- WLAC N/A
- NBTX N/A
- EPS
- WLAC N/A
- NBTX N/A
- Revenue
- WLAC N/A
- NBTX $45,220,186.00
- Revenue This Year
- WLAC N/A
- NBTX N/A
- Revenue Next Year
- WLAC N/A
- NBTX N/A
- P/E Ratio
- WLAC N/A
- NBTX N/A
- Revenue Growth
- WLAC N/A
- NBTX 526.17
- 52 Week Low
- WLAC $9.95
- NBTX $2.76
- 52 Week High
- WLAC $10.50
- NBTX $7.51
- Technical
- Relative Strength Index (RSI)
- WLAC N/A
- NBTX 53.25
- Support Level
- WLAC N/A
- NBTX $3.60
- Resistance Level
- WLAC N/A
- NBTX $3.95
- Average True Range (ATR)
- WLAC 0.00
- NBTX 0.19
- MACD
- WLAC 0.00
- NBTX -0.01
- Stochastic Oscillator
- WLAC 0.00
- NBTX 38.18
About WLAC Willow Lane Acquisition Corp. Class A Ordinary Shares
Willow Lane Acquisition Corp is a blank check company.
About NBTX Nanobiotix S.A.
Nanobiotix SA is a clinical-stage biotechnology company that has one operating segment, which focuses on developing product candidates that use its proprietary nanotechnology to transform cancer treatment by increasing the efficacy of radiotherapy. The company develops NanoXray products to help patients receiving radiotherapy by magnifying the effect of radiotherapy within tumor cells without increasing the dose to surrounding healthy tissues. Its product candidate is NBTXR3, a preclinical research program for cancer immunotherapies.